In vitro effects of meloxicam on metabolism in articular chondrocytes from dogs with naturally occurring osteoarthritis
OBJECTIVE: To assess effects of in vitro meloxicam exposure on metabolism in articular chondrocytes from dogs with naturally occurring osteoarthritis.
SAMPLE: Femoral head cartilage from 16 dogs undergoing total hip replacement.
PROCEDURES: Articular cartilage samples were obtained. Tissue sulfated glycosaminoglycan (SGAG), collagen, and DNA concentrations were measured. Collagen, SGAG, chondroitin sulfate 846, NO, prostaglandin E2 (PGE2), and matrix metalloproteinase (MMP)-2, MMP-3, MMP-9, and MMP-13 concentrations in culture medium were analyzed. Aggrecan, collagen II, MMP-2, MMP-3, MMP-9, MMP-13, ADAM metallopeptidase with thrombospondin type 1 motif (ADAMTS)-4, ADAMTS-5, tissue inhibitor of metalloproteinase (TIMP)-1, TIMP-2, TIMP-3, interleukin-1β, tumor necrosis factor-α, cyclooxygenase-1, cyclooxygenase-2, and inducible nitric oxide synthase gene expression were evaluated. Comparisons between tissues cultured without (control) and with meloxicam at concentrations of 0.3, 3.0, and 30.0 μg/mL for up to 30 days were performed by means of repeated-measures analysis.
RESULTS: Meloxicam had no effect on chondrocyte SGAG, collagen, or DNA concentrations. Expression of ADAMTS-5 was significantly decreased in all groups on all days, compared with the day 0 value. On day 3, culture medium PGE2 concentrations were significantly lower in all meloxicam-treated groups, compared with values for controls, and values remained low. Culture medium MMP-3 concentrations were significantly lower on day 30 than on day 3 in all meloxicam-treated groups.
CONCLUSIONS AND CLINICAL RELEVANCE: Results suggested that in vitro meloxicam treatment of osteoarthritic canine cartilage for up to 30 days did not induce matrix degradation or stimulate MMP production. Meloxicam lowered PGE2 release from this tissue, and effects on tissue chondrocyte content and matrix composition were neutral.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2013 |
|---|---|
| Erschienen: |
2013 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:74 |
|---|---|
| Enthalten in: |
American journal of veterinary research - 74(2013), 9 vom: 24. Sept., Seite 1198-205 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Budsberg, Steven C [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 17.03.2014 Date Revised 02.12.2018 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2460/ajvr.74.9.1198 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM230328490 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM230328490 | ||
| 003 | DE-627 | ||
| 005 | 20231224084151.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2460/ajvr.74.9.1198 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0767.xml |
| 035 | |a (DE-627)NLM230328490 | ||
| 035 | |a (NLM)23977892 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Budsberg, Steven C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a In vitro effects of meloxicam on metabolism in articular chondrocytes from dogs with naturally occurring osteoarthritis |
| 264 | 1 | |c 2013 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.03.2014 | ||
| 500 | |a Date Revised 02.12.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVE: To assess effects of in vitro meloxicam exposure on metabolism in articular chondrocytes from dogs with naturally occurring osteoarthritis | ||
| 520 | |a SAMPLE: Femoral head cartilage from 16 dogs undergoing total hip replacement | ||
| 520 | |a PROCEDURES: Articular cartilage samples were obtained. Tissue sulfated glycosaminoglycan (SGAG), collagen, and DNA concentrations were measured. Collagen, SGAG, chondroitin sulfate 846, NO, prostaglandin E2 (PGE2), and matrix metalloproteinase (MMP)-2, MMP-3, MMP-9, and MMP-13 concentrations in culture medium were analyzed. Aggrecan, collagen II, MMP-2, MMP-3, MMP-9, MMP-13, ADAM metallopeptidase with thrombospondin type 1 motif (ADAMTS)-4, ADAMTS-5, tissue inhibitor of metalloproteinase (TIMP)-1, TIMP-2, TIMP-3, interleukin-1β, tumor necrosis factor-α, cyclooxygenase-1, cyclooxygenase-2, and inducible nitric oxide synthase gene expression were evaluated. Comparisons between tissues cultured without (control) and with meloxicam at concentrations of 0.3, 3.0, and 30.0 μg/mL for up to 30 days were performed by means of repeated-measures analysis | ||
| 520 | |a RESULTS: Meloxicam had no effect on chondrocyte SGAG, collagen, or DNA concentrations. Expression of ADAMTS-5 was significantly decreased in all groups on all days, compared with the day 0 value. On day 3, culture medium PGE2 concentrations were significantly lower in all meloxicam-treated groups, compared with values for controls, and values remained low. Culture medium MMP-3 concentrations were significantly lower on day 30 than on day 3 in all meloxicam-treated groups | ||
| 520 | |a CONCLUSIONS AND CLINICAL RELEVANCE: Results suggested that in vitro meloxicam treatment of osteoarthritic canine cartilage for up to 30 days did not induce matrix degradation or stimulate MMP production. Meloxicam lowered PGE2 release from this tissue, and effects on tissue chondrocyte content and matrix composition were neutral | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Anti-Inflammatory Agents, Non-Steroidal |2 NLM | |
| 650 | 7 | |a Glycosaminoglycans |2 NLM | |
| 650 | 7 | |a Thiazines |2 NLM | |
| 650 | 7 | |a Thiazoles |2 NLM | |
| 650 | 7 | |a Tissue Inhibitor of Metalloproteinases |2 NLM | |
| 650 | 7 | |a A73025 |2 NLM | |
| 650 | 7 | |a 268AW7000T |2 NLM | |
| 650 | 7 | |a RNA |2 NLM | |
| 650 | 7 | |a 63231-63-0 |2 NLM | |
| 650 | 7 | |a Collagen |2 NLM | |
| 650 | 7 | |a 9007-34-5 |2 NLM | |
| 650 | 7 | |a Matrix Metalloproteinases |2 NLM | |
| 650 | 7 | |a EC 3.4.24.- |2 NLM | |
| 650 | 7 | |a Meloxicam |2 NLM | |
| 650 | 7 | |a VG2QF83CGL |2 NLM | |
| 700 | 1 | |a Stoker, Aaron M |e verfasserin |4 aut | |
| 700 | 1 | |a Johnston, Spencer A |e verfasserin |4 aut | |
| 700 | 1 | |a Liska, William |e verfasserin |4 aut | |
| 700 | 1 | |a Reno, Lisa R |e verfasserin |4 aut | |
| 700 | 1 | |a Cook, James L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of veterinary research |d 1945 |g 74(2013), 9 vom: 24. Sept., Seite 1198-205 |w (DE-627)NLM000012718 |x 1943-5681 |7 nnns |
| 773 | 1 | 8 | |g volume:74 |g year:2013 |g number:9 |g day:24 |g month:09 |g pages:1198-205 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2460/ajvr.74.9.1198 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 74 |j 2013 |e 9 |b 24 |c 09 |h 1198-205 | ||